ALS Biomarker Detection via Xenobiotic Metabolic Profiling
Solution Overview
Problem
Current methods lack effective biomarkers for diagnosing, predicting, and monitoring amyotrophic lateral sclerosis (ALS), as well as assessing treatment efficacy, due to the complexity of the disease and limited understanding of its metabolic imbalances.
Innovation Solution
Identification and utilization of specific biomarkers such as xenobiotics and their metabolites, like caffeine and its metabolites, to diagnose ALS, predict predisposition, monitor disease progression, and evaluate treatment effectiveness through metabolic profiling and statistical analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for ALS, then the disease can be diagnosed, but the diagnostic accuracy and ability to differentiate from other neurodegenerative diseases is insufficient
Solution Approach 1:
The patent segments the diagnostic approach by identifying and measuring specific individual biomarkers (xenobiotics and metabolites) separately rather than using conventional general neurological assessments. This segmentation allows for more precise differentiation of ALS from other neurodegenerative diseases through specific metabolic profiles.
Solution Approach 2:
The patent changes the measurement parameters from conventional neurological symptoms to specific metabolic parameters (levels of xenobiotics and metabolites). This parameter change enables more accurate diagnosis by detecting characteristic metabolic alterations associated with ALS, such as changes in caffeine metabolism and other xenobiotic processing markers.
2Measurement precision
If metabolic profiling of xenobiotics and metabolites is performed, then diagnostic accuracy improves, but the complexity of analysis and interpretation increases
Solution Approach 1:
The patent applies a universal metabolic profiling approach that can detect multiple biomarkers (various xenobiotics and metabolites) using the same analytical framework. This multi-functional method allows simultaneous assessment of different metabolic pathways, reducing the need for multiple separate tests and simplifying the overall diagnostic process despite the complexity of individual measurements.
Data Source
AI summary
The present invention provides various biomarkers of amyotrophic lateral sclerosis (ALS). The present invention also provides various methods of using the biomarkers, including methods for diagnosis of ALS, methods of determining predisposition to ALS, methods of monitoring progression/regression of ALS, methods of assessing efficacy of compositions for treating ALS, methods of screening compositions for activity in modulating biomarkers of ALS, methods of treating ALS, as well as other methods based on biomarkers of ALS.